Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor

Biomaterials

Volumn 104, Issue , 2016, Pages 119-128

  Kumar, Rajesh ^a   Kim, Eun Joong ^b   Han, Jiyou ^a   Lee, Hyunseung ^b   Shin, Weon Sup ^a   Kim, Hyun Min ^b   Bhuniya, Sankarprasad ^c   Kim, Jong Seung ^a   Hong, Kwan Soo ^b  

^a Korea University   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

^c AMRITA SCHOOL OF ENGINEERING   (India)

Author keywords

Anti tumor; Hypoxia; Prodrug; Solid tumor; Theranostic

Indexed keywords

FLUOROPHORES; TUMORS;

ANTI-TUMORS; HYPOXIA; PRODRUGS; SOLID TUMORS; THERANOSTIC;

DIAGNOSIS;

AMINO ACID; BIOTIN DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CARBOXYLESTERASE; CASPASE 3; CASPASE 9; CYSTINE; DNA FRAGMENT; DNA TOPOISOMERASE; FIRTECAN; GENOMIC DNA; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; IRINOTECAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; VITAMIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUORESCENT DYE; OXYGEN;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; FLUORESCENCE IMAGING; HELA CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TAIL VEIN; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR SPHEROID; TUMOR XENOGRAFT; A-549 CELL LINE; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; PATHOLOGY; PROCEDURES; THERANOSTIC NANOMEDICINE; TREATMENT OUTCOME; TUMOR HYPOXIA;

A549 CELLS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL PROLIFERATION; FLUORESCENT DYES; HELA CELLS; HUMANS; NEOPLASMS, EXPERIMENTAL; OXYGEN; THERANOSTIC NANOMEDICINE; TREATMENT OUTCOME; TUMOR HYPOXIA;

EID: 84978767500     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.07.010     Document Type: Article

References (34)

1. [1] Csete, M., Oxygen in the cultivation of stem cells. Ann. N. Y. Acad. Sci. 1049 (2005), 1–8.
2. [2] Wilson, W.R., Hay, M.P., Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11 (2011), 393–410.
3. [3] Brown, J.M., Wilson, W.R., Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4 (2004), 437–447.
4. [4] Tannock, I.F., Conventional cancer therapy: promise broken or promise delayed?. Lancet 351:Suppl. 2 (1998), SII9–16.
5. [5] Durand, R.E., The influence of microenvironmental factors during cancer therapy. In. Vivo 8 (1994), 691–702.
6. [6] Tannock, I.F., The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br. J. Cancer 22 (1968), 258–273.
7. [7] Comerford, K.M., Wallace, T.J., Karhausen, J., Louis, N.A., Montalto, M.C., Colgan, S.P., Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62 (2002), 3387–3394.
8. [8] Wartenberg, M., Ling, F.C., Muschen, M., Klein, F., Acker, H., Gassmann, M., et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 17 (2003), 503–505.
9. [9] Yuan, J., Glazer, P.M., Mutagenesis induced by the tumor microenvironment. Mutat. Res. 400 (1998), 439–446.
10. [10] Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., Comoglio, P.M., Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 3 (2003), 347–361.
11. [11] Harris, A.L., Hypoxia–a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002), 38–47.
12. [12] Subarsky, P., Hill, R.P., The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20 (2003), 237–250.
13. [13] Perche, F., Biswas, S., Wang, T., Zhu, L., Torchilin, V.P., Hypoxia-targeted siRNA delivery. Angew. Chem. Int. Ed. Engl. 53 (2014), 3362–3366.
14. [14] Yuan, Y., Kwok, R.T., Tang, B.Z., Liu, B., Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. J. Am. Chem. Soc. 136 (2014), 2546–2554.
15. [15] Janib, S.M., Moses, A.S., MacKay, J.A., Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62 (2010), 1052–1063.
16. [16] Jokerst, J.V., Gambhir, S.S., Molecular imaging with theranostic nanoparticles. Acc. Chem. Res. 44 (2011), 1050–1060.
17. [17] Piao, W., Tsuda, S., Tanaka, Y., Maeda, S., Liu, F., Takahashi, S., et al. Development of azo-based fluorescent probes to detect different levels of hypoxia. Angew. Chem. Int. Ed. Engl. 52 (2013), 13028–13032.
18. [18] Li, Y., Sun, Y., Li, J., Su, Q., Yuan, W., Dai, Y., et al. Ultrasensitive near-infrared fluorescence-enhanced probe for in vivo nitroreductase imaging. J. Am. Chem. Soc. 137 (2015), 6407–6416.
19. [19] Zheng, X., Wang, X., Mao, H., Wu, W., Liu, B., Jiang, X., Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo. Nat. Commun. 6 (2015), 1–12.
20. [20] Gulaka, P.K., Rojas-Quijano, F., Kovacs, Z., Mason, R.P., Sherry, A.D., Kodibagkar, V.D., GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo. J. Biol. Inorg. Chem. 19 (2014), 271–279.
21. [21] Kelada, O.J., Carlson, D.J., Molecular imaging of tumor hypoxia with positron emission tomography. Radiat. Res. 181 (2014), 335–349.
22. [22] Kiyose, K., Hanaoka, K., Oushiki, D., Nakamura, T., Kajimura, M., Suematsu, M., et al. Hypoxia-sensitive fluorescent probes for in vivo real-time fluorescence imaging of acute ischemia. J. Am. Chem. Soc. 132 (2010), 15846–15848.
23. [23] Tanabe, K., Hirata, N., Harada, H., Hiraoka, M., Nishimoto, S., Emission under hypoxia: one-electron reduction and fluorescence characteristics of an indolequinone-coumarin conjugate. Chembiochem 9 (2008), 426–432.
24. [24] Huang, H.C., Wang, K.L., Huang, S.T., Lin, H.Y., Lin, C.M., Development of a sensitive long-wavelength fluorogenic probe for nitroreductase: a new fluorimetric indictor for analyte determination by dehydrogenase-coupled biosensors. Biosens. Bioelectron. 26 (2011), 3511–3516.
25. [25] Pommier, Y., Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6 (2006), 789–802.
26. [26] Mathijssen, R.H., van Alphen, R.J., Verweij, J., Loos, W.J., Nooter, K., Stoter, G., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7 (2001), 2182–2194.
27. [27] Jaffar, M., Williams, K.J., Stratford, I.J., Bioreductive and gene therapy approaches to hypoxic diseases. Adv. Drug Deliv. Rev. 53 (2001), 217–228.
28. [28] Ren, W.X., Han, J., Uhm, S., Jang, Y.J., Kang, C., Kim, J.H., et al. Recent development of biotin conjugation in biological imaging, sensing, and target delivery. Chem. Commun. (Camb) 51 (2015), 10403–10418.
29. [29] Jung, J.W., Park, S.B., Lee, S.J., Seo, M.S., Trosko, J.E., Kang, K.S., Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One, 6, 2011, e28068.
30. [30] Wang, G.L., Jiang, B.H., Rue, E.A., Semenza, G.L., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 5510–5514.
31. [31] Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003), 721–732.
32. [32] Murono, K., Tsuno, N.H., Kawai, K., Sasaki, K., Hongo, K., Kaneko, M., et al. SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha. Anticancer Res. 32 (2012), 865–872.
33. [33] Catley, L., Tai, Y.T., Shringarpure, R., Burger, R., Son, M.T., Podar, K., et al. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 64 (2004), 8746–8753.
34. [34] Chen, Y.R., Wang, X., Templeton, D., Davis, R.J., Tan, T.H., The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem. 271 (1996), 31929–31936.